Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).
Hurvitz SA, Caswell-Jin JL, McNamara KL, Zoeller JJ, Bean GR, Dichmann R, Perez A, Patel R, Zehngebot L, Allen H, Bosserman L, DiCarlo B, Kennedy A, Giuliano A, Calfa C, Molthrop D, Mani A, Chen HW, Dering J, Adams B, Kotler E, Press MF, Brugge JS, Curtis C, Slamon DJ. Hurvitz SA, et al. Among authors: molthrop d. Nat Commun. 2020 Nov 17;11(1):5824. doi: 10.1038/s41467-020-19494-2. Nat Commun. 2020. PMID: 33203854 Free PMC article. Clinical Trial.
Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy.
Yardley DA, Peacock N, Daniel B, Anz B, Molthrop DC Jr, Shroff SK, Young R, Jankov A, Vander Woude A, Shastry M, Pasek J, DeBusk LM, Hainsworth JD. Yardley DA, et al. Among authors: molthrop dc jr. Breast Cancer Res Treat. 2020 Apr;180(3):647-655. doi: 10.1007/s10549-020-05563-z. Epub 2020 Feb 14. Breast Cancer Res Treat. 2020. PMID: 32060783 Clinical Trial.